aromatase inhibitor

アロマターゼ阻害薬、アロマターゼ阻害剤、アロマターゼインヒビター

WordNet

1. limit, block, or decrease the action or function of; "inhibit the action of the enzyme"; "inhibit the rate of a chemical reaction"
2. control and refrain from showing; of emotions, desires, impulses, or behavior (同)bottle up, suppress
3. limit the range or extent of; "Contact between the young was inhibited by strict social customs"
4. a substance that retards or stops an activity

PrepTutorEJDIC

1. 〈感情・欲望・行動・作用など〉‘を'抑制する / (…しないように)〈人〉‘を'抑制する,妨げる《+『名』+『from』+『名』(do『ing』)》
2. 抑制する人(物) / 化学反応抑制剤

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2017/10/22 10:28:51」(JST)

wiki en

[Wiki en表示]

Aromatase inhibitor
Drug class
Anastrozole, a nonsteroidal aromatase inhibitor and a widely used drug in the treatment of breast cancer.
Class identifiers
Synonyms	Estrogen synthesis inhibitors; Estrogen synthase inhibitors; Estrogen blockers
Use	Breast cancer, infertility, precocious puberty, medical abortion, gynecomastia, endometriosis, short stature, others
ATC code	L02BG
Biological target	Aromatase
Chemical class	Steroidal; Nonsteroidal
In Wikidata

Aromatase inhibitors (AIs) are a class of drugs used in the treatment of breast cancer in postmenopausal women and gynecomastia in men. They may also be used off-label to reduce estrogen conversion when using external testosterone. They may also be used for chemoprevention in high risk women.

Aromatase is the enzyme that synthesizes estrogen. As breast and ovarian cancers require estrogen to grow, AIs are taken to either block the production of estrogen or block the action of estrogen on receptors.

Medical uses

Cancer

In contrast to premenopausal women, in whom most of the estrogen is produced in the ovaries, in postmenopausal women estrogen is mainly produced in peripheral tissues of the body. Because some breast cancers respond to estrogen, lowering estrogen production at the site of the cancer (i.e. the adipose tissue of the breast) with aromatase inhibitors has been proven to be an effective treatment for hormone-sensitive breast cancer in postmenopausal women. Aromatase inhibitors are generally not used to treat breast cancer in premenopausal women. When aromatase inhibitors are used in premenopausal women, the decrease in estrogen activates the hypothalamus and pituitary axis to increase gonadotropin secretion, which in turn stimulates the ovary to increase androgen production. The heightened gonadotropin levels also upregulate the aromatase promoter, increasing aromatase production in the setting of increased androgen substrate. This counteracts the effect of the aromatase inhibitor in premenopausal women since total estrogen is increased. Ongoing areas of clinical research is optimizing adjuvant hormonal therapy in postmenopausal women with breast cancer. Although tamoxifen (SERM) had been the traditional drug treatment of choice, the ATAC trial has shown that clinical results are superior with an AI in postmenopausal women with localized breast cancer that is estrogen receptor positive. Trials of AIs in the adjuvant setting (given to prevent relapse after surgery for breast cancer) show that they are associated with a better disease-free survival than tamoxifen, but few conventionally-analyzed clinicals trials have shown that AIs have an overall survival advantage compared with tamoxifen, and there is no good evidence they are better tolerated.

Gynecomastia

Aromatase inhibitors such as testolactone have been approved for the treatment of gynecomastia in children and adolescents.

Unexplained female infertility

Ovarian stimulation with the aromatase inhibitor letrozole has been proposed as one of the treatments for unexplained female infertility. In a multi-center study funded by the National Institute of Child Health and Development, ovarian stimulation with letrozole resulted in a significantly lower frequency of multiple gestation (i.e., twins or triplets) but also a lower frequency of live birth, as compared with gonadotropin but not with clomiphene.

Side effects

Side effects include an increased risk for developing osteoporosis and joint disorders such as arthritis, arthrosis, and joint pain. Bisphosphonates are sometimes prescribed to prevent the osteoporosis induced by aromatase inhibitors, but also have another serious side effect, osteonecrosis of the jaw. As statins have a bone strengthening effect, combining a statin with an aromatase inhibitor could help prevent fractures and suspected cardiovascular risks, without potential of causing osteonecrosis of the jaw. The more common adverse events associated with the use of aromatase inhibitors include decreased rate of bone maturation and growth, infertility, aggressive behavior, adrenal insufficiency, kidney failure, hair loss, and liver dysfunction. Patients with liver, kidney or adrenal abnormalities are at a higher risk of developing adverse events.

Mechanism of action

Often used as a cancer treatment in postmenopausal women, AIs work by blocking the conversion of androstenedione and testosterone into estrone and estradiol, respectively, which are both crucial to the growth of developing breast cancers (AIs are also effective at treating ovarian cancer, but less commonly so). In the diagram, the adrenal gland (1) releases androstenedione (3) while the ovaries (2) secrete testosterone (4). Both hormones travel to peripheral tissues or a breast cell (5), where they would be converted into estrone (8) or estradiol (9) if not for AIs (7), which prevent the enzyme CYP19A1 (also known as aromatase or estrogen synthase) (6) from catalyzing the reaction that turns androstenedione and testosterone into estrone and estradiol. In the diagram, Part A represents the successful conversion of androstenedione and testosterone into estrone and estradiol in the liver. Part B represents the blockage of this conversion by aromatase inhibitors both in peripheral tissues and in the breast tumor itself.

Aromatase inhibitors work by inhibiting the action of the enzyme aromatase, which converts androgens into estrogens by a process called aromatization. As breast tissue is stimulated by estrogens, decreasing their production is a way of suppressing recurrence of the breast tumor tissue. The main source of estrogen is the ovaries in premenopausal women, while in post-menopausal women most of the body's estrogen is produced in peripheral tissues (outside the CNS), and also a few CNS sites in various regions within the brain. Estrogen is produced and acts locally in these tissues, but any circulating estrogen, which exerts systemic estrogenic effects in men and women, is the result of estrogen escaping local metabolism and spreading to the circulatory system.

Types

There are two types of aromatase inhibitors approved to treat breast cancer:

• Irreversible steroidal inhibitors, such as exemestane (Aromasin), forms a permanent and deactivating bond with the aromatase enzyme.
• Nonsteroidal inhibitors, such as anastrozole (Arimidex) and letrozole (Femara), inhibit the synthesis of estrogen via reversible competition for the aromatase enzyme.

See also: Steroidal Aromatase Inhibitors

Members

Arimidex (anastrozole) 1 mg tablets

Available aromatase inhibitors (AIs) include:

Non-selective

• Aminoglutethimide, also inhibits the enzyme P450scc and so decreases synthesis of all steroid hormones.
• Testolactone (Teslac)

Selective

• Anastrozole (Arimidex)
• Letrozole (Femara)
• Exemestane (Aromasin)
• Vorozole (Rivizor)
• Formestane (Lentaron)
• Fadrozole (Afema)

Unknown

• 1,4,6-Androstatrien-3,17-dione (ATD)
• 4-Androstene-3,6,17-trione ("6-OXO")

In addition to pharmaceutical AIs, some natural elements have aromatase inhibiting effects, such as damiana leaves.

Research

Investigations and research has been undertaken to study the use of aromatase inhibitors to stimulate ovulation, and also to suppress estrogen production. Aromatase inhibitors have been shown to reverse age-related declines in testosterone, including primary hypogonadism. Extracts of certain mushrooms have been shown to inhibit aromatase when evaluated by enzyme assays, with white mushroom having shown the greatest ability to inhibit the enzyme. AIs have also been used experimentally in the treatment of adolescents with delayed puberty.

Table mushroom

Research suggests the common table mushroom has anti-aromatase properties and therefore possible anti-estrogen activity. In 2009, a case-control study of the eating habits of 2,018 women in southeast China revealed that women who consumed greater than 10 grams of fresh mushrooms or greater than 4 grams of dried mushrooms per day had an approximately 50% lower incidence of breast cancer. Chinese women who consumed mushrooms and green tea had a 90% lower incidence of breast cancer. However the study was relatively small (2,018 patients participating) and limited to Chinese women of southeast China.

See also

• Selective estrogen receptor degrader
• Estrogen deprivation therapy
• CYP17A1 inhibitor

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

• 1. 非転移性ホルモン受容体陽性乳癌に対する補助内分泌療法 adjuvant endocrine therapy for non metastatic hormone receptor positive breast cancer
• 2. 乳癌予防のための選択的エストロゲン受容体調節因子およびアロマターゼ阻害剤 selective estrogen receptor modulators and aromatase inhibitors for breast cancer prevention
• 3. アロマターゼ阻害剤による骨量減少の評価およびマネージメント evaluation and management of aromatase inhibitor induced bone loss
• 4. 転移性ホルモン受容体陽性乳癌に対する治療アプローチ：内分泌療法 treatment approach to metastatic hormone receptor positive breast cancer endocrine therapy
• 5. アロマターゼ阻害剤による排卵誘発 ovulation induction with aromatase inhibitors

English Journal

• Noninfectious pneumonitis with the use of mTOR inhibitors in breast cancer.

• Peddi PF, Shatsky RA, Hurvitz SA.SourceDepartment of Medicine, Division of Hematology-Oncology, University of California, Los Angeles, CA 90404, USA. Electronic address: ppeddi@mednet.ucla.edu.
• Cancer treatment reviews.Cancer Treat Rev.2014 Mar;40(2):320-6. doi: 10.1016/j.ctrv.2013.08.004. Epub 2013 Aug 14.
• The mammalian target of rapamycin (mTOR) inhibitor class of drugs represents the newest addition to the armamentarium of therapies for hormonally driven breast cancer. It has recently been shown that the addition of mTOR inhibitor everolimus to aromatase inhibitors in hormone receptor-positive breas
• PMID 24011786

• Neoadjuvant hormonal therapy for endocrine sensitive breast cancer: A systematic review.

• Charehbili A, Fontein DB, Kroep JR, Liefers GJ, Mieog JS, Nortier JW, van de Velde CJ.SourceDepartment of Surgery, Leiden University Medical Center, Leiden, The Netherlands; Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands.
• Cancer treatment reviews.Cancer Treat Rev.2014 Feb;40(1):86-92. doi: 10.1016/j.ctrv.2013.06.001. Epub 2013 Jul 23.
• In recent years, studies investigating neoadjuvant therapies have been emerging, because of the additional benefits it provides in terms of facilitating less extensive surgery and the possibility of investigating tumor biological features and response. Neoadjuvant hormonal therapy (NHT) is, in gener
• PMID 23891267

• Understanding response and resistance to oestrogen deprivation in ER-positive breast cancer.

• Patani N, Martin LA.SourceAcademic Department of Biochemistry, Royal Marsden Foundation Trust, London, UK; Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London SW3 6JB, UK.
• Molecular and cellular endocrinology.Mol Cell Endocrinol.2014 Jan 25;382(1):683-94. doi: 10.1016/j.mce.2013.09.038. Epub 2013 Oct 9.
• Oestrogens (E) and oestrogen receptor alpha (ERα) play fundamental roles in the development and progression of more than three-quarters of breast cancers (BC). The ability to influence the natural history of BC by hormonal manipulation is well established and endocrine therapies represent the corne
• PMID 24121024

Japanese Journal

• Investigation of antiaromatase activity using hepatic microsomes of Nile tilapia (<i>Oreochromis niloticus</i>)

• Drug Discoveries & Therapeutics, 2017
• NAID 130005464524

• 血性乳頭分泌を伴った乳腺神経内分泌性腫瘍の１例

• 信州医学雑誌 65(1), 45-49, 2017
• NAID 130005397651

• 臨床経験 Aromatase InhibitorおよびDienogestを組み合わせた粘膜下病変を伴う子宮腺筋症に対する新しい治療戦略

• 産婦人科の実際 = Obstetrical and gynecological practice 65(9), 1097-1100, 2016-09
• NAID 40020962243

Related Links

• Aromatase inhibitor - Wikipedia, the free encyclopedia

Aromatase inhibitors work by inhibiting the action of the enzyme aromatase, which converts androgens into estrogens by a process called aromatization. As breast tissue is stimulated by estrogens, decreasing their production is a way of ...

• Aromatase Inhibitors - Breastcancer.org

17 Sep 2012 ... Aromatase inhibitors stop the production of estrogen in postmenopausal women. Aromatase inhibitors work by blocking the enzyme aromatase, which turns the hormone androgen into small amounts of estrogen in the body.

Related Pictures

---

★リンクテーブル★

リンク元	「アロマターゼ阻害薬」
拡張検索	「aromatase inhibitors」
関連記事	「inhibit」「inhibitor」

「アロマターゼ阻害薬」

　　[★]

英

aromatase inhibitor

同

アロマターゼ阻害剤、アロマターゼインヒビター

関

アロマターゼ

「aromatase inhibitors」

　　[★] アロマターゼ阻害薬

「inhibit」

　　[★]

• v.

• 抑制する、阻害する、阻止する

関

abrogate、block、depress、depression、deter、inhibition、interdict、prevent、prevention、repress、repression、restrain、restraint、suppress、suppression

　 　 　 　

「inhibitor」

　　[★]

• n.

• 阻害剤、阻害薬、抑制薬、抑制剤、(内在性物質について)インヒビター、抑制物質

関

blocker、depressant、suppressant